Johnson & Johnson Earnings: Showing Surprising Weakness

Johnson & Johnson  had what on the surface appeared to be a pretty good quarter -- revenue and earnings were up solidly year-over-year, and the pharma business grew like a weed.

But looking under the surface, things didn't appear nearly as positive. And in the video below, Motley Fool health care analyst Michael Douglass lays out his concerns with Johnson & Johnson and what he thinks about this top dividend stock.

This coming blockbuster will make even Johnson & Johnson jealous
The best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


The article Johnson & Johnson Earnings: Showing Surprising Weakness originally appeared on Fool.com.

Alison Southwick owns shares of CVS Health. Michael Douglass owns shares of Johnson & Johnson and Gilead Sciences. The Motley Fool recommends CVS Health, Gilead Sciences, and Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story